Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Noemie Lang

Geneve, GE, CH 
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Geneve, GE, CH 
OverviewLocationsClinical Research

Overview

Noemie Lang practices in Geneve, Switzerland. Ms. Lang is rated as an Experienced expert by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Agranulocytosis.

Her clinical research consists of co-authoring 23 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Monoclonal Gammopathy of Undetermined Significance (MGUS).

Gender
Female

Locations

Geneve, GE, Switzerland
Other Locations
Lausanne, VD, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial.
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
Study Drug: Acalabrutinib
Study Phase: Phase 2
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. A Multicenter Phase Ib Trial With Two Expansion Cohorts
Enrollment Status: Terminated
Publish Date: April 01, 2022
Intervention Type: Drug
Study Drugs: Copanlisib, Venetoclax
Study Phase: Phase 1
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drugs: Ibrutinib, Bortezomib
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

23 Total Publications

Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.
Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.
Journal: JCO precision oncology
Published: July 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lang's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile